Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On February 11, 2026, Steve O'Loughlin tendered his resignation as the Chief Financial Officer of Actinium Pharmaceuticals, Inc. (the "Company"), effective as of February 27, 2026, to pursue other opportunities (the "Effective Date"). There were no disagreements with the Company that contributed to Mr. O'Loughlin's resignation.

Additionally, on February 13, 2026, to fill the executive vacancy as a result of Mr. O'Loughlin's resignation as the principal financial officer of the Company, the Board appointed Sandesh Seth, the current Chairman and Chief Executive Officer of the Company, to serve as the principal financial officer, effective as of the Effective Date.

Mr. Sandesh Seth has been the Chief Executive Officer of the Company since June 2017. Mr. Seth has been a Director since March 2012, the Company's Chairman of the Board since October 2013, and served as Executive Chairman from August 2014 to June 2017. Mr. Seth has 25 plus years of experience in investment banking (Laidlaw& Co (UK) Ltd., Cowen & Co.), equity research (Bear Stearns, Commonwealth Associates) and in the pharma industry (Pfizer, Warner-Lambert, SmithKline in strategic planning, business development and R&D project management). Mr. Seth was chairman of Relmada Therapeutics Inc., a specialty pharma company focused on CNS therapeutics, which he helped co-found. Mr. Seth has an MBA in Finance from New York University, an M.S. in the Pharmaceutical Sciences from the University of Oklahoma Health Center and a B.Sc. in Chemistry from Bombay University. He has published several scientific articles and was awarded the University Regents Award for Research Excellence at the University of Oklahoma. Mr. Seth was designated as Regulatory Affairs Certified by the Regulatory Affairs Professionals Society which signifies proficiency with U.S. FDA regulations. He has several patents related to the use of radiopharmaceuticals as conditioning agents for adoptive cell therapies and as therapeutic combinations.

There are no family relationships between Mr. Seth and any director or executive officer of the Company that would be required to be disclosed pursuant to Item 401(d) of Regulation S-K, and there are no transactions involving Mr. Seth that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.